A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Abroad (travel likely)RecruitingPHASE2
Conditions
Systemic Sclerosis Associated Interstitial Lung Disease · Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD) · Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Peking University Third Hospital, Beijing, Beijing Municipality, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (qibing xie, Doctor of Medicine(M.D.) · xieqibing1971@163.com · 13808175616
Study leads
qibing xie, Doctor of Medicine(M.D.)
Study Chair
West China Hospital